
Already we have began to see the impact of the Index as companies, that have embraced the Index, have began to use it as a tool for broadening CRS programs into greater business strategies.
In addition, it is our goal that the Index becomes:
• A tool to assist companies develop, implement and measure the direction of their access to medicine programs
• A way for companies to benchmark and share best practices within and across sectors
• For articulating, clarifying, and uniting the dialogue around ‘access’ issue with internal and external stakeholders from institutional investors to nonprofits.
• Positively stimulates investments in access to medicine programs of large pharmaceutical companies.